Premium
Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab
Author(s) -
Richetta Antonio Giovanni,
Maiani Elisa,
Carlomagno Valentina,
Carboni Valentina,
Mattozzi Carlo,
Giancristoforo Simona,
Calvieri Stefano
Publication year - 2009
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2009.01266.x
Subject(s) - medicine , psoriasis , ribavirin , adalimumab , pegylated interferon , dermatology , hepatitis c virus , hepatitis c , rescue therapy , immunology , virus , tumor necrosis factor alpha
Erythrodermic psoriasis is a severe and disabling variant of psoriasis. The authors present the case of a 48‐year‐old man with psoriasis and hemophilia presented with a history of hepatitis C virus (HCV) infection treated with pegylated interferon alpha‐2a and ribavirin therapy. At the end of antiviral therapy, skin manifestation progressively worsened, becoming erythrodermic, with lack of efficacy of steroid therapy. The authors decided to start biological therapy with induction dose of adalimumab (Humira, Abbott Laboratories, Abbott Park, Chicago, IL) 80 mg at Week 0 and 40 mg weekly. In our case, this resulted in a highly effective and safe treatment.